The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Advances in immunotherapy for multiple myeloma: CAR-T, bispecifics, and trispecifics
Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, highlights the advances being made in immunotherapy for multiple myeloma. She discusses the promising long-term outcomes of CAR T-cell therapy and notes the potential of novel bispecific and trispecific antibodies. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’ve heard a lot at the meeting about different immunotherapy approaches in myeloma. Obviously, we also have long-term follow-up data that was recently published from the CARTITUDE-1 trial, looking at long-term outcomes for patients who had cilta-cel in relapsed disease and showing, you know, really promising durable results for a subgroup of patients within that study who were able to have long periods of disease remission without needing to have ongoing treatment...
We’ve heard a lot at the meeting about different immunotherapy approaches in myeloma. Obviously, we also have long-term follow-up data that was recently published from the CARTITUDE-1 trial, looking at long-term outcomes for patients who had cilta-cel in relapsed disease and showing, you know, really promising durable results for a subgroup of patients within that study who were able to have long periods of disease remission without needing to have ongoing treatment. That’s part of the benefit of CAR-T approaches. But we’re also hearing a lot about novel bispecific and even trispecific antibody therapies that are starting to read out results as well in similar populations. These are in terms of data output coming a little later than the initial CAR-T data, but still showing really promising results in patients with relapsed/refractory disease. But also, we’re hoping to see results from the trials in patients with one to three prior lines of therapy reading out towards the end of this year as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Abbvie: Honoraria; GSK: Honoraria; Janssen: Honoraria; Pfizer: Honoraria; BMS/Celgene: Honoraria, Membership on an entity’s Board of Directors or advisory committees; iTEOS Therapeutics: Honoraria; Menarini Stemline: Honoraria; Sanofi: Honoraria.
